TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30714482

Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (trained with functional words)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (trained with words from a picture database)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-administered therapy using a smart tablet (exposed but not trained)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not exposed)
Number of subjects: 5
Study: 29799130

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tumor incision (sham surgery)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Macroscopic complete resection (MCR) in patients
Number of subjects: 27
Study: 28102427

Group type: EXPERIMENTAL
Intervention: 250 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 500 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 270

Group type: COMPARATOR
Intervention: 300 mg oral acetylsalicylic acid (ASA)
Number of subjects: 270
Study: 25692350

Group type: EXPERIMENTAL
Intervention: 4-dose Zagreb regimen
Number of subjects: 600

Group type: COMPARATOR
Intervention: 5-dose Essen regimen
Number of subjects: 600
Study: 23835708

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus pemetrexed 500 mg/m(2)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 376
Study: 20042475

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1) i.v. as a bolus and 15 mg kg(‐1) h(‐1) by continuous infusion during the operation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 61
Study: 19032711

Group type: EXPERIMENTAL
Intervention: Multifamily group therapy plus pharmacotherapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Individual family therapy plus pharmacotherapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 53
Study: 16595599

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11799338

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day, increased to 100 mg after 4 weeks if inadequate response)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9718016

Group type: EXPERIMENTAL
Intervention: Active suction drainage
Number of subjects: 101

Group type: COMPARATOR
Intervention: Passive chest drainage
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 7917732

Group type: EXPERIMENTAL
Intervention: Active skin surface warming (forced heated air, Bair‐Hugger)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Passive skin surface warming (metallized plastic sheet, Thermolite)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no intraoperative warming device)
Number of subjects: 45
Study: 2779240

Group type: EXPERIMENTAL
Intervention: Alcohol (0.125 g/kg of 95% ethanol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alcohol (0.25 g/kg of 95% ethanol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg of 95% ethanol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Concurrent schedule of point presentation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Interaction between alcohol and concurrent point presentation contingencies
Number of subjects: 6

Group type: COMPARATOR
Intervention: No alcohol (0 g/kg of 95% ethanol)
Number of subjects: 6
Study: 177873

Group type: EXPERIMENTAL
Intervention: Radiation with high-dose metronidazole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 36
Study: 30032673

Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 33

Group type: COMPARATOR
Intervention: 20 mg pyridoxine (placebo)
Number of subjects: 33
Study: 25983332

Group type: EXPERIMENTAL
Intervention: Integration of health promotion (HP), occupational health and safety (OHS), and kaizen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no integration of HP, OHS, and kaizen)
Number of subjects: 12
Study: 24854755

Group type: EXPERIMENTAL
Intervention: Lifting gasless laparoscopic myomectomy with 5 mm laparoscope and 2 abdominal holes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pneumoperitoneum laparoscopic myomectomy
Number of subjects: 90
Study: 22049171

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20464816

Group type: EXPERIMENTAL
Intervention: Older pilots (41+ years)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Younger pilots (under 41 years)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Older IFR/CFI pilots
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Younger IFR/CFI pilots
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Younger CFII/ATP pilots
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Older CFII/ATP pilots
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pilots with faster processing speed
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pilots with slower processing speed
Number of subjects: 72
Study: 18666223

Group type: EXPERIMENTAL
Intervention: alb-IFN 900 microg q2wk
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: alb-IFN 1200 microg q2wk
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: alb-IFN 1200 microg q4wk
Number of subjects: 458

Group type: COMPARATOR
Intervention: PEG-IFNalpha-2a 180 microg qwk
Number of subjects: 458

Group type: COMPARATOR
Intervention: PEG-IFNalpha-2a
Number of subjects: 458
Study: 15769244

Group type: EXPERIMENTAL
Intervention: Participants who overheard peers discussing a fair reputation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Participants who overheard peers discussing an unfair reputation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Participants who heard no prior information about the experimenter
Number of subjects: 105
Study: 12799881

Group type: EXPERIMENTAL
Intervention: Medical and surgical treatment for GERD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 10780828

Group type: EXPERIMENTAL
Intervention: Alcohol preload
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Juice preload
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 22
Study: 7718367

Group type: EXPERIMENTAL
Intervention: i.m. ketorolac 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: morphine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 2074061

Group type: EXPERIMENTAL
Intervention: Psychological preparation (cognitive-behavioral program, 'stress inoculation')
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention-placebo group (control)
Number of subjects: 40
Study: 7006805

Group type: EXPERIMENTAL
Intervention: ICRF‐159
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5‐FU
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ICRF‐159 (crossover after 5‐FU)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5‐FU (crossover after ICRF‐159)
Number of subjects: 37
Study: 29368298

Group type: EXPERIMENTAL
Intervention: Web-based multidomain intervention (nutritional counseling, physical and cognitive trainings) with connected accelerometer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group with access to general information on healthy aging plus the accelerometer
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Web-based multidomain intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27237762

Group type: EXPERIMENTAL
Intervention: Modified clinical Pilates exercises (2 times a week for 10 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 11
Study: 24045635

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (ECH) 8,000 mgd(‐1) for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA) wheat flour for 6 weeks
Number of subjects: 16
Study: 22104568

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait‐list control
Number of subjects: 41
Study: 20032007

Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg three times per week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16845552

Group type: EXPERIMENTAL
Intervention: WMSD patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: WAD patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: WMSD and WAD patients
Number of subjects: 61
Study: 15947534

Group type: EXPERIMENTAL
Intervention: HeartMate XVE Left Ventricular Assist Device (LVAD)
Number of subjects: 42
Study: 11837717

Group type: EXPERIMENTAL
Intervention: Alprostadil alfadex at a dose of 0.05 microg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alprostadil alfadex at a dose of 0.1 microg/kg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study: 10368359

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day for 3 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ibuprofen and Placebo
Number of subjects: 16
Study: 8712438

Group type: EXPERIMENTAL
Intervention: Technique 1 (SIB compressed before connection)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Technique 2 (SIB compressed after connection)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Technique 2 (after delivery of three breaths)
Number of subjects: 54
Study: 1817935

Group type: EXPERIMENTAL
Intervention: One-step excavation of deep carious lesions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stepwise method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histology (both methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbiological examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic pulp inflammations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflammation-free pulps
Number of subjects: 0
Study: 6897860

Group type: EXPERIMENTAL
Intervention: DOPP (doxorubicin, oncovin, procarbazine and prednisolone)
Number of subjects: 37

Group type: COMPARATOR
Intervention: MOPP (mustine, oncovin, procarbazine and prednisolone)
Number of subjects: 37
Study: 31606244

Group type: EXPERIMENTAL
Intervention: Fish oil (840 mg EPA and 560 mg DHA per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (paraffin oil)
Number of subjects: 0
Study: 30206011

Group type: EXPERIMENTAL
Intervention: HeProCalc algorithm
Number of subjects: 210

Group type: COMPARATOR
Intervention: Traditional heparin and protamine dosage based on body weight (Control group)
Number of subjects: 210
Study: 29232964

Group type: EXPERIMENTAL
Intervention: Family Finding intervention
Number of subjects: 568
Study: 26919870

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mm Hg or 10 mm Hg reduction from baseline if this was <140 mm Hg)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Standard target (<140 mm Hg)
Number of subjects: 529
Study: 24060523

Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Amlodipine (CCB group)
Number of subjects: 48
Study: 22156892

Group type: EXPERIMENTAL
Intervention: Buprenorphine (20 μg/h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fentanyl (25 μg/h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20676814

Group type: EXPERIMENTAL
Intervention: Immediate loading within the first week after insertion
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional loading after a 12-week healing phase
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both loading groups
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 41
Study: 17343594

Group type: EXPERIMENTAL
Intervention: Collagen-polyvinylpyrrolidone (clg-pvp) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline solution with polyvinylpyrrolidone) applied at a rate of 1.5 ml intradermically at four equi-spaced points around the ulcer.
Number of subjects: 0
Study: 15766828

Group type: EXPERIMENTAL
Intervention: Snuff tobacco
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12108897

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 (D75)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 (D100)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Vinorelbine/Ifosfamide (V/I)
Number of subjects: 577
Study: 10468470

Group type: EXPERIMENTAL
Intervention: 3-dimensional tuned-aperture computed tomography (TACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional periapical and/or panoramic radiographs
Number of subjects: 0
Study: 8315700

Group type: EXPERIMENTAL
Intervention: Day hospital program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient program
Number of subjects: 0
Study: 3808504

Group type: EXPERIMENTAL
Intervention: strict management (euglycemic: fasting blood glucose < 80 mg/dL, 1.5-hour postprandial blood glucose < 120 mg/dL)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: customary management (fasting blood glucose ≤ 100 mg/dL, postprandial blood glucose < 140 mg/dL)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: management identical to customary management (for group III)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (infants of nondiabetic mothers)
Number of subjects: 254
Study: 30269060

Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured by the Center for Epidemiologic Studies Depression scale
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Poor academic performance
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Higher consumption of unhealthy food
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Negative self-perception about body shape
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: General health status
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Limited physical activeness
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences including physical violence
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Psychological abuse during childhood
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Lack of general and medical care by family during childhood
Number of subjects: 1359
Study: 27073975

Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family requests for early withdrawal of life support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Communication gaps related to prognostic uncertainty
Number of subjects: 0
Study: 24275233

Group type: EXPERIMENTAL
Intervention: Sharp incision with scissors
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Blunt manual cleavage of the fascia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pain scores
Number of subjects: 34
Study: 22561092

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact Control (CC)
Number of subjects: 0
Study: 20421229

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 32
Study: 17700438

Group type: EXPERIMENTAL
Intervention: Physical therapy added to general practitioners' care
Number of subjects: 135

Group type: COMPARATOR
Intervention: General practitioners' care alone
Number of subjects: 135
Study: 16292118

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 52

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 52
Study: 12183711

Group type: EXPERIMENTAL
Intervention: Organized lipid matrix (OLM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Triacylglycerol (TG)
Number of subjects: 76
Study: 10190520

Group type: EXPERIMENTAL
Intervention: Isosorbide‐isoproterenol test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Isoproterenol test
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 96
Study: 8942589

Group type: EXPERIMENTAL
Intervention: IV droperidol 1.25 mg and ondansetron 4 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: IV droperidol 1.25 mg and saline
Number of subjects: 120
Study: 2039720

Group type: EXPERIMENTAL
Intervention: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 325 nm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 352 nm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral 8‐methoxypsoralen photochemotherapy (PUVA) using ultraviolet fluorescent lamps with peak emission at 370 nm
Number of subjects: 24
Study: 7129805

Group type: EXPERIMENTAL
Intervention: 75 mg nomifensine intravenously
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 150 mg nomifensine orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: 75 mg nomifensine orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine (both forms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 10
Study: 31624048

Group type: EXPERIMENTAL
Intervention: 1 Hz cerebellar repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 23
Study: 31520608

Group type: EXPERIMENTAL
Intervention: Hygroscopic dilators with misoprostol 400 mcg
Number of subjects: 163

Group type: COMPARATOR
Intervention: No hygroscopic dilators with misoprostol 400 mcg
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol
Number of subjects: 163

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 163
Study: 28676254

Group type: EXPERIMENTAL
Intervention: Patient navigation by two bilingual lay navigators providing individualized education and support
Number of subjects: 843

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 843
Study: 26553689

Group type: EXPERIMENTAL
Intervention: PsA‐TT
Number of subjects: 0

Group type: COMPARATOR
Intervention: PsACWY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PsA‐TT (2 doses)
Number of subjects: 0
Study: 23732344

Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 167

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 167
Study: 21175981

Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion (Actrapid 2 IU/h) during dialysis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional dialysis
Number of subjects: 11
Study: 19140915

Group type: EXPERIMENTAL
Intervention: Sums of the amplitudes of the ECG QRS complexes from leads I and II
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sums of the amplitudes of the six limb leads
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sums of the amplitudes of the V1-V6 leads
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sums of the amplitudes of all 12 leads
Number of subjects: 20
Study: 17197581

Group type: EXPERIMENTAL
Intervention: TVT (tension-free vaginal tape) procedure
Number of subjects: 267

Group type: COMPARATOR
Intervention: TVT-O (transobturator tension-free vaginal tape) procedure
Number of subjects: 267
Study: 15095806

Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular (ATVV) multisensory intervention twice daily from 33 weeks postconceptional age until hospital discharge
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no multisensory intervention)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular (ATVV) multisensory intervention
Number of subjects: 37
Study: 11407078

Group type: EXPERIMENTAL
Intervention: BioHy (high molecular weight hyaluronic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9921004

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Aurothiomalate
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 97
Study: 9480464

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 54
Study: 2198303

Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg/day, titrated to a maximum of 90 mg/day)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Buspirone (40 mg/day)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Gepirone (analogue of buspirone)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 572722

Group type: EXPERIMENTAL
Intervention: Refined carbohydrate diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standardised diet with low refined carbohydrate
Number of subjects: 18
Study: 30409085

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with 3-4 daily serves of dairy food (MedDairy)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-fat (LF) control diet
Number of subjects: 41
Study: 30905230

Group type: EXPERIMENTAL
Intervention: Canola oil (20 mL/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amaranth oil (20 mL/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 28422805

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 21